Company Profile
EyePoint Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- EYPT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
12.83 USD (+4.73%)
Close
Last updated: August 6, 2026
1.05B USD
Market cap
Why the stock is moving
Following the latest company update, “EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments”, EYPT closed up 4.97% at $12.25 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Retinal Disease Focus
EyePoint Pharmaceuticals develops sustained-delivery therapies for serious retinal diseases. Its programs are designed to reduce the treatment burden associated with frequent intravitreal injections while maintaining durable control of retinal vascular disease.
DURAVYU Technology
DURAVYU combines vorolanib, a selective tyrosine kinase inhibitor, with EyePoint’s bioerodible Durasert E delivery technology. The product candidate is designed to provide extended intraocular drug exposure and inhibit multiple pathways involved in retinal disease.
Wet AMD Pivotal Program
The identical LUGANO and LUCIA Phase 3 trials evaluate DURAVYU against on-label aflibercept in wet age-related macular degeneration. This program represents the company’s nearest major efficacy readout and follows supportive Phase 2 findings from DAVIO 2.
Diabetic Macular Edema Expansion
EyePoint is also evaluating DURAVYU in the COMO and CAPRI Phase 3 trials for diabetic macular edema. The studies extend the same sustained-delivery platform into another large retinal market and use six-month redosing.
Future catalysts
Topline results from the Phase 3 LUGANO wet AMD trial expected beginning in mid-2026, followed by results from LUCIA.
Completion of enrollment in the COMO and CAPRI Phase 3 DME trials expected in the third quarter of 2026.
Topline results from the Phase 3 DME program anticipated in the fourth quarter of 2027.
Recent news
- 01
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
Source: EyePoint Pharmaceuticals
- 02
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
Source: EyePoint Pharmaceuticals
- 03
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Source: EyePoint Pharmaceuticals
- 04
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
Source: EyePoint Pharmaceuticals
- 05
EyePoint Announces Participation at Upcoming Investor Conferences
Source: EyePoint Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of EyePoint Pharmaceuticals (EYPT)?
EyePoint Pharmaceuticals (EYPT) most recently closed at 12.83 USD, a +4.73% move versus the previous session.
What is the market cap of EyePoint Pharmaceuticals (EYPT)?
EyePoint Pharmaceuticals currently has a market capitalization of 1.05B USD on BioPharmSignal.
What does EyePoint Pharmaceuticals do?
Retinal Disease Focus EyePoint Pharmaceuticals develops sustained-delivery therapies for serious retinal diseases. Its programs are designed to reduce the treatment burden associated with frequent intravitreal injections while maintaining durable control of retinal vascular disease. DURAVYU Technology DURAVYU combines vorolanib, a selective tyrosine kinase...
On which exchange is EYPT stock listed?
EyePoint Pharmaceuticals (EYPT) is associated with NASDAQ, United States, Biopharma.
What is vorolanib?
DURAVYU Technology DURAVYU combines vorolanib, a selective tyrosine kinase inhibitor, with EyePoint’s bioerodible Durasert E delivery technology.
Which conditions is EyePoint Pharmaceuticals targeting with vorolanib?
Retinal Disease Focus EyePoint Pharmaceuticals develops sustained-delivery therapies for serious retinal diseases. Its programs are designed to reduce the treatment burden associated with frequent intravitreal injections while maintaining durable control of retinal vascular disease. DURAVYU Technology DURAVYU combines vorolanib, a selective tyrosine kinase...
How does EyePoint Pharmaceuticals describe recent progress with vorolanib?
Topline results from the Phase 3 LUGANO wet AMD trial expected beginning in mid-2026, followed by results from LUCIA. Completion of enrollment in the COMO and CAPRI Phase 3 DME trials expected in the third quarter of 2026. Topline results from the Phase 3 DME program anticipated in the fourth quarter of 2027.
What is aflibercept?
Wet AMD Pivotal Program The identical LUGANO and LUCIA Phase 3 trials evaluate DURAVYU against on-label aflibercept in wet age-related macular degeneration.